key: cord-0723884-4mjg7jul
authors: Siripanthong, Bhurint; Nazarian, Saman; Muser, Daniele; Deo, Rajat; Santangeli, Pasquale; Khanji, Mohammed Y.; Cooper, Leslie T.; Chahal, C. Anwar A.
title: Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management
date: 2020-05-05
journal: Heart Rhythm
DOI: 10.1016/j.hrthm.2020.05.001
sha: 83284b9347ee9b89e6a621525740b95e443c10ee
doc_id: 723884
cord_uid: 4mjg7jul

Abstract Human coronavirus-associated myocarditis is known, and a number of COVID-19-related myocarditis cases have been reported. The pathophysiology of COVID-19-related myocarditis is thought to be a combination of direct viral injury and cardiac damage due to the host’s immune response. COVID-19 myocarditis diagnosis should be guided by insights from previous coronavirus and other myocarditis experience. The clinical findings include changes in ECG, cardiac biomarkers, and impaired cardiac function. When cardiac MRI is infeasible, cardiac CT angiography with delayed myocardial imaging may serve to exclude significant coronary artery disease and identify myocardial inflammatory patterns. Because many COVID-19 patients have cardiovascular comorbidities, myocardial infarction should be considered. Where the diagnosis remains uncertain, an endomyocardial biopsy may help identify active cardiac infection through viral genome amplification and possibly refine the treatment risks of systemic immunosuppression. Arrhythmias are not uncommon in the COVID-19 patients; however, its pathophysiology is still speculative. Nevertheless, clinicians should be vigilant to provide prompt monitoring and treatments. The long-term impact of COVID-19 myocarditis, including in the majority of mild cases remains unknown.

Severe acute respiratory syndrome coronavirus 2

Funding: This contemporary review did not receive any specific grant from funding agencies 36 in the public, commercial, or not-for-profit sectors. 37

In December 2019, COVID-19 was first described in Wuhan, China, in patients complaining 57 of flu-like symptoms. 1 The virus was isolated and identified as a new strain of coronavirus, 58 now named SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2). Mortality 59 rate of COVID-19 is estimated to be below 1%, 2 mainly due to the severe acute respiratory 60 syndrome and multi-organ dysfunction. Cardiovascular complications of COVID-19 received 61 less medical attention; nevertheless, the first cases of myocarditis in COVID- 19 patients have 62 been reported. [3] [4] [5] [6] Moreover, myocarditis was recognized as the cause of death in some 63 COVID-19 patients. 7 Pathology is usually focal within the myocardium, but there is a risk of 64 arrhythmia, as well as progression to fulminant heart failure and cardiogenic shock. This 65 article outlines the possible pathophysiology of COVID-19-related myocarditis, its clinical 66 presentation, as well as the associated arrhythmias. The criteria for screening and 67 management of myocarditis relating to COVID-19 are also proposed. Myocarditis is an inflammatory disease of the heart characterized by inflammatory infiltrates 72 and myocardial injury without an ischemic cause. 8 The most commonly identifiable cause of 73 myocarditis in the United States other developed countries is viral. 9 , 10 Esfandiarei and 74

McManus 8 proposed that the pathophysiology of viral myocarditis is a combination of direct 75 cell injury and T-lymphocytes-mediated cytotoxicity which can be augmented by the 76 cytokine storm syndrome. Interleukin-6 (IL-6) appears to be the central mediator of cytokine 77 storm where it orchestrates the pro-inflammatory responses from immune cells including the 78 T-lymphocytes. 11 This causes T-lymphocyte activation and a further release of inflammatory 79 cytokines which stimulate more T-lymphocytes, leading to a positive feedback loop of 80 immune activation and myocardial damage. Cardiotropism of the T-lymphocytes is thought 81 to arise from the interaction between the heart-produced hepatocyte growth factor (HGF) and 82 c-Met, a HGF receptor on naïve T-lymphocytes. 12 Despite being a minor cause of all viral myocarditis cases, human coronaviruses have been 86 linked to myocarditis in patients of all age groups. [13] [14] [15] The viral RNAs of MERS-CoV and 87 SARS-CoV, which are close relatives of SARS-CoV-2, were found in the heart tissues of 88 infected animals, suggesting that these coronaviruses possess cardiotropism. 16 Possible pathophysiology of SARS-CoV-2-related myocarditis 100 SARS-CoV-2 gains entry into the human cells by binding its spike protein to a membrane 101 protein, Angiotensin-Converting Enzyme 2 (ACE2). 20 However, the spike protein must first 102 be cleaved at the S1/S2 and subsequently at the S2' sites to enable binding to the ACE2. 103

Cleavage at the S1/S2 site appears to be mediated by TMPRSS2, a serine protein. 20 The 104 ACE2 can be found on the ciliated columnar epithelial cells of the respiratory tract, type II 105 pneumocytes as well as cardiomyocytes. 21, 22 Therefore, it is plausible that SARS-CoV-2 106

infects the human heart, especially when there is heart failure since ACE2 is upregulated, 23 107 although the presence of viral receptors does not always predict tropism. 24 108

There are at least 6 known accessory proteins which can be transcribed by the SARS-CoV-2 110 genome. 25 It remains to be determined whether any of the accessory proteins do provide 111 infectivity advantage as in MERS-CoV and SARS-CoV. 

It is unclear how prevalent myocarditis is among COVID-19 patients. This is partly because 117 the early reports often lacked the specific diagnostic modalities to assess myocarditis. Some 118 argued that up to 7% of the COVID-19-related deaths were attributable to myocarditis; 26 119 however, this was assumed and not based on a confirmatory diagnosis of myocarditis and 120 may be an overestimate. On the other hand, many laboratories are rationing tests and first 121 screening for known pathogens resulting in flu-like symptoms. If a positive pathogen is 122 identified, then testing for SARS-CoV-2 is not performed. This is erroneous and likely to 123 miss the true frequency of SARS-CoV-2 infection as it assumes mutual exclusivity of SARS-124

CoV-2. One report has identified 24.5% of COVID-19 patients to have co-infection with 125 other viruses. 27 Hence, it is possible that many cases of COVID-19-related myocarditis were 126 missed due to a lack of SARS-CoV-2 diagnosis. 127

Certain ethnic groups may be disproportionately affected by SARS-CoV-2. COVID-19 death 129 rates were shown to be higher among the African-American population than other ethnicities 130 in many American states. 28 Whilst this may partially be explained by the higher 131 cardiovascular risk factors or genetic predisposition to poorer cardiac outcomes, 29 Hubei, China reported a 7.3% incidence of heart palpitations among its 137 patients. 30 140

Moreover, Wang et al. 31 reported that arrhythmia was a cause of ICU transfer in 44.4% of 141 COVID-19 patients. Caution is encouraged when interpreting these data as the sample size 142 tends to be small and hence prone to overestimation. The exact nature of the arrhythmias was 143 also not usually reported, rendering it difficult to assess whether they are secondary to other 144 conditions such as electrolyte imbalance or pre-existing arrhythmias. The actual prevalence 145 of arrhythmias in COVID-19 patients; therefore, remains unknown. Nevertheless, 146 arrhythmias could occur in the context of myocarditis. Peretto et al. 32 reported in a recent 147 study that 78.7% of myocarditis patients exhibited some forms of ventricular arrhythmias. 148

The characteristics of arrhythmias also differ between the active and healed myocarditis, 32 149 suggesting that the pathophysiology is dependent on the stage of myocardial injury. shown that pro-inflammatory cytokines, e.g. IL-6, might cause the displacement of 159 plakoglobin, a desmosomal protein, from the cardiomyocyte membrane. 35 This could be 160 arrhythmogenic as inadequate cell-to-cell adherence is postulated to damage the cell 161 membrane, leading to cardiac cell death and fibrofatty replacement. 36 Moreover, reduced 162 surface expression of desmosomal proteins is a known etiology of arrhythmogenic 163 cardiomyopathies. 36 Substantial evidence has now suggested an increase in serum IL-6 in 164 COVID-19 patients, especially in those with severe presentations. 37 It is, therefore, plausible 165 that SARS-CoV-2 infection precipitates arrhythmias in patients with a genetic predisposition. of tachycardia and acute-onset heart failure with cardiogenic shock. [3] [4] [5] In these severe cases, 176 patients may also present with signs of right-sided heart failure, including raised jugular 177 venous pressure, peripheral edema and right upper quadrant pain. 10 The most emergent 178 presentation is fulminant myocarditis, defined by ventricular dysfunction and heart failure 179 within 2-3 weeks of contracting the virus. 8 The early signs of fulminant myocarditis usually 180 resemble those of sepsis; i.e., a patient often presents febrile with low pulse pressure, cold or 181 mottled periphery and sinus tachycardia. 10 Sepsis-related cardiomyopathy: A case series study showed that 67% of critically-ill 220 COVID-19 patients required vasopressor and that 33% developed cardiomyopathy. 40 This 221 raises suspicion of sepsis-related cardiomyopathy, a disease characterized by reversible 222 myocardial dysfunction. The myocardial injury is thought to arise from raised nitric oxide 223 production which suppresses the cardiomyocyte's response to calcium and downregulates the 224 heart's 1-adrenergic receptors. 41 The three cardinal signs of sepsis-related cardiomyopathy Takotsubo cardiomyopathy is usually preceded by an emotional or physical stressor. 42 Of 233 note, a case report described a COVID-19 patient who initially presented as having reverse 234 an effective alternative, especially when the patient is to undertake the high-resolution CT 255 scan of the chest for assessment of the acute respiratory distress syndrome (Figure 3J) . 256

Contrast-enhanced cardiac CT will add very little scanning time, and it is particularly useful 257 in this situation to perform a test rapidly with minimal requirement for breath-holding. 44 

Without the CMR or contrast-enhanced CT results, it is arduous to distinguish myocarditis 259 from other differential diagnoses. and RNA-DNA extraction performed to test for the presence of viral genomes. 45 Regarding 266

the contagious spread risk, should coronary angiography be deemed necessary, it is 267 reasonable to perform the right heart procedures and/or EMB concomitantly as these will add 268 minimal risk, whilst adding 15-minutes to the procedure time. It also serves as an opportunity 269 for accurate diagnosis and provides tissues for the development of specific biomarkers which 270 could be useful for developing a diagnostic test for SARS-CoV-2 myocarditis. In the tragic 271 situation where a patient is deceased, we suggest that an autopsy be performed and include 272 the heart as this provides an opportunity to observe its gross and microscopic pathology, are not undergoing clinical testing such as an ECG or cardiac imaging. As the emphasis is to 282 evaluate and admit patients with severe lower respiratory tract symptoms, many patients with 283 possible myocarditis will never be evaluated. Some of these may survive the acute event but 284 may be at risk of subsequent arrhythmias. In a study of patients with active and healed 285 myocarditis, monomorphic ventricular tachycardia and regular ventricular arrhythmias were 286 more frequent in healed than acute myocarditis. 32 involves mechanical circulatory support such as extracorporeal membrane oxygenation, 297 ventricular assist device, or intra-aortic balloon pump. The ESC did not endorse the use of 298 intravenous immunoglobulin due to a lack of supporting evidence, 9 and discouraged the use 299 of corticosteroids in active-infection myocarditis, citing the ineffectiveness of corticosteroids 300 in a randomized-controlled trial. 46 

Case reports of coronavirus-related myocarditis provide a glimpse into the efficacy of some 303 of the aforementioned treatments. Supplemental Table 1 is a summary of 9 case reports on 304 patients with coronavirus-related myocarditis. Mechanical circulatory support was deployed 305 in 2/7 cases (where treatment modalities were reported). 3, 47 Presumably, in a more 306 hemodynamically stable case, medical treatment consisting of inotropes or vasopressors was 307 sufficient to mitigate the ventricular systolic dysfunction. 4, 13, 48 In some cases, 308 immunomodulatory treatments were given; Zeng et al. (2020) 3 in COVID-19. Currently, chloroquine is under a phase IIb clinical trial to assess its efficacy 332 in treating COVID-19 patients with severe respiratory syndrome. 52 Both chloroquine and its 333 derivative, hydroxychloroquine, may cause QTc interval prolongation; however, their effects 334 appear to be modest. 51 Nevertheless, (hydroxy)chloroquine requires metabolism by the 335 CYP3A4 enzyme 53 whose inhibition might raise the drug's plasma concentration, 

A novel coronavirus from patients with pneumonia in China

Covid-19: death rate is 0.66% and increases with age, study estimates

First case of COVID-19 infection with fulminant myocarditis complication: case report and insights

Cardiac Involvement in a Patient with Coronavirus Disease 2019 (COVID-19)

COVID-19-related myocarditis in a 21-year-old female patient

Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine

Molecular Biology and Pathogenesis of Viral Myocarditis

Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association

Current concepts in the diagnosis and management of cytokine release syndrome

Hepatocyte Growth Factor Receptor c-Met Instructs T Cell Cardiotropism and Promotes T Cell Migration to the Heart via Autocrine Chemokine Release

Tachycardie atriale chaotique au cours d'une infection respiratoire à coronavirus NL63. Archives de Pediatrie

CARDITIS ASSOCIATED WITH CORONAVIRUS INFECTION. The Lancet

Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus

Generation of a Transgenic Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease

An immunosuppressed Syrian golden hamster model for SARS-CoV infection

Inhibition of Stress Granule Formation by Middle East Respiratory Syndrome Coronavirus 4a Accessory Protein Facilitates Viral Translation, Leading to Efficient Virus Replication

Severe Acute Respiratory Syndrome Coronavirus nsp1 Suppresses Host Gene Expression, Including That of Type I Interferon, in Infected Cells

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus

ACE2 gene expression is up-regulated in the human failing heart

Single-cell RNA Analysis on ACE2 Expression Provides Insight into SARS-CoV-2 Blood Entry and Heart Injury. medRxiv

Forty years with coronaviruses

The architecture of SARS-CoV-2 transcriptome [Internet]. bioRxiv. Cold Spring Harbor Laboratory

03.12.988865

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic

Higher co-infection rates in COVID19 -Nigam Shah -Medium

COVID-19 and African Americans

Association of Variants in BAG3 with Cardiomyopathy Outcomes in African American Individuals

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in

Ventricular Arrhythmias in Myocarditis: Characterization and Relationships With Myocardial Inflammation

Arrhythmias in myocarditis: State of the art

The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2

Altered desmosomal proteins in granulomatous myocarditis and potential pathogenic links to arrhythmogenic right ventricular cardiomyopathy

Arrhythmogenic right ventricular cardiomyopathy

Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis. medRxiv

Troponin and BNP Use in COVID-19

COVID-19) and Cardiovascular Disease

Characteristics and Outcomes of 21 Critically Ill Patients with COVID-19 in Washington State

A review of sepsis-induced cardiomyopathy

Pathophysiology of Takotsubo Syndrome. Circulation. Lippincott Williams and Wilkins

Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper

Interstitial myocardial fibrosis assessed as extracellular volume fraction with low-radiation-dose cardiac CT

Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology

A clinical trial of immunosuppressive therapy for myocarditis

Coronavirus Associated Fulminant Myocarditis Successfully Treated With Intravenous Immunoglobulin and Extracorporeal Membrane Oxygenation

Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin

Corticosteroids and Intravenous Immunoglobulin in Pediatric Myocarditis: A Meta-Analysis. Frontiers in Pediatrics

Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019 -Full Text View -ClinicalTrials.gov [Internet

Journal Pre-proof SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes

Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded

Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes

Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia. Chinese Journal of Tuberculosis and Respiratory Diseases Chinese Medical

Addresses Concerns Re: Using RAAS Antagonists in COVID-19 -American College of Cardiology

ΔΔ: 1. ACS 2. Sepsis-related cardiomyopathy

Myocarditis (focal or fulminant)

Stress-induced cardiomyopathy (Takotsubo) or new arrhythmias • Cardiogenic, distributive or mixed shock • New right heart failure COVID-19 patient suspected myocarditis • Daily ECG (new conduction abnormality) • Cardiac enzymes

• Inflammatory markers (CRP and/or ESR) • Handheld US or Transthoracic Echocardiogram (TTE) Bedside tests • Repeat TTE • Perform CMR if possible • CT-CA or invasive angiogram for ACS • Contrast-enhanced cardiac CT if cannot do CMR or doing high-resolution CT chest